nodes	percent_of_prediction	percent_of_DWPC	metapath
Nilotinib—CYP2C8—Montelukast—chronic obstructive pulmonary disease	0.0356	0.108	CbGbCtD
Nilotinib—CYP2C9—Formoterol—chronic obstructive pulmonary disease	0.0327	0.0995	CbGbCtD
Nilotinib—CYP2C9—Arformoterol—chronic obstructive pulmonary disease	0.0327	0.0995	CbGbCtD
Nilotinib—CYP2D6—Formoterol—chronic obstructive pulmonary disease	0.0299	0.091	CbGbCtD
Nilotinib—CYP2D6—Arformoterol—chronic obstructive pulmonary disease	0.0299	0.091	CbGbCtD
Nilotinib—CYP2D6—Tiotropium—chronic obstructive pulmonary disease	0.0267	0.0811	CbGbCtD
Nilotinib—CYP3A4—Salbutamol—chronic obstructive pulmonary disease	0.0251	0.0763	CbGbCtD
Nilotinib—CYP2C9—Montelukast—chronic obstructive pulmonary disease	0.0248	0.0754	CbGbCtD
Nilotinib—CYP3A4—Tiotropium—chronic obstructive pulmonary disease	0.017	0.0516	CbGbCtD
Nilotinib—CYP3A4—Aminophylline—chronic obstructive pulmonary disease	0.0162	0.0492	CbGbCtD
Nilotinib—CYP3A4—Montelukast—chronic obstructive pulmonary disease	0.0144	0.0438	CbGbCtD
Nilotinib—ABCB1—Prednisolone—chronic obstructive pulmonary disease	0.0141	0.0429	CbGbCtD
Nilotinib—ABCB1—Prednisone—chronic obstructive pulmonary disease	0.0133	0.0405	CbGbCtD
Nilotinib—EPHA2—pulmonary artery—chronic obstructive pulmonary disease	0.00972	0.0662	CbGeAlD
Nilotinib—CYP3A4—Prednisolone—chronic obstructive pulmonary disease	0.00847	0.0257	CbGbCtD
Nilotinib—CYP3A4—Prednisone—chronic obstructive pulmonary disease	0.008	0.0243	CbGbCtD
Nilotinib—CDC42BPB—respiratory system—chronic obstructive pulmonary disease	0.00306	0.0208	CbGeAlD
Nilotinib—MAPK8—respiratory system—chronic obstructive pulmonary disease	0.00277	0.0188	CbGeAlD
Nilotinib—CDC42BPB—bronchus—chronic obstructive pulmonary disease	0.00252	0.0171	CbGeAlD
Nilotinib—CDC42BPB—smooth muscle tissue—chronic obstructive pulmonary disease	0.00246	0.0168	CbGeAlD
Nilotinib—MAPK8—connective tissue—chronic obstructive pulmonary disease	0.00244	0.0166	CbGeAlD
Nilotinib—TIE1—respiratory system—chronic obstructive pulmonary disease	0.0024	0.0163	CbGeAlD
Nilotinib—MAPK8—bronchus—chronic obstructive pulmonary disease	0.00228	0.0155	CbGeAlD
Nilotinib—CDC42BPB—trachea—chronic obstructive pulmonary disease	0.00226	0.0154	CbGeAlD
Nilotinib—LYN—connective tissue—chronic obstructive pulmonary disease	0.00225	0.0153	CbGeAlD
Nilotinib—MAPK8—smooth muscle tissue—chronic obstructive pulmonary disease	0.00223	0.0152	CbGeAlD
Nilotinib—MAP4K1—bronchus—chronic obstructive pulmonary disease	0.00207	0.0141	CbGeAlD
Nilotinib—TIE1—smooth muscle tissue—chronic obstructive pulmonary disease	0.00193	0.0132	CbGeAlD
Nilotinib—CA3—respiratory system—chronic obstructive pulmonary disease	0.00188	0.0128	CbGeAlD
Nilotinib—EPHB3—bronchus—chronic obstructive pulmonary disease	0.00188	0.0128	CbGeAlD
Nilotinib—MAPK14—respiratory system—chronic obstructive pulmonary disease	0.00176	0.012	CbGeAlD
Nilotinib—FGR—respiratory system—chronic obstructive pulmonary disease	0.00175	0.0119	CbGeAlD
Nilotinib—HCK—bronchus—chronic obstructive pulmonary disease	0.00173	0.0118	CbGeAlD
Nilotinib—EPHB3—trachea—chronic obstructive pulmonary disease	0.00169	0.0115	CbGeAlD
Nilotinib—EPHB4—respiratory system—chronic obstructive pulmonary disease	0.00167	0.0113	CbGeAlD
Nilotinib—CA3—connective tissue—chronic obstructive pulmonary disease	0.00166	0.0113	CbGeAlD
Nilotinib—EPHA2—respiratory system—chronic obstructive pulmonary disease	0.00164	0.0111	CbGeAlD
Nilotinib—CDC42BPB—lung—chronic obstructive pulmonary disease	0.00163	0.0111	CbGeAlD
Nilotinib—TEK—respiratory system—chronic obstructive pulmonary disease	0.0016	0.0109	CbGeAlD
Nilotinib—EPHA4—bronchus—chronic obstructive pulmonary disease	0.00157	0.0107	CbGeAlD
Nilotinib—HCK—trachea—chronic obstructive pulmonary disease	0.00155	0.0106	CbGeAlD
Nilotinib—MAPK14—connective tissue—chronic obstructive pulmonary disease	0.00155	0.0105	CbGeAlD
Nilotinib—EPHA3—lung—chronic obstructive pulmonary disease	0.00154	0.0105	CbGeAlD
Nilotinib—CA7—trachea—chronic obstructive pulmonary disease	0.00152	0.0103	CbGeAlD
Nilotinib—EPHB2—Diflorasone—Prednisone—chronic obstructive pulmonary disease	0.00149	0.506	CbGdCrCtD
Nilotinib—MAPK8—lung—chronic obstructive pulmonary disease	0.00147	0.01	CbGeAlD
Nilotinib—EPHB4—connective tissue—chronic obstructive pulmonary disease	0.00147	0.00999	CbGeAlD
Nilotinib—EPHB2—Diflorasone—Prednisolone—chronic obstructive pulmonary disease	0.00145	0.494	CbGdCrCtD
Nilotinib—MAPK14—bronchus—chronic obstructive pulmonary disease	0.00145	0.00985	CbGeAlD
Nilotinib—PDGFRA—respiratory system—chronic obstructive pulmonary disease	0.00145	0.00984	CbGeAlD
Nilotinib—LCK—bronchus—chronic obstructive pulmonary disease	0.00144	0.00981	CbGeAlD
Nilotinib—MAPK14—smooth muscle tissue—chronic obstructive pulmonary disease	0.00142	0.00964	CbGeAlD
Nilotinib—EPHA4—trachea—chronic obstructive pulmonary disease	0.00141	0.00959	CbGeAlD
Nilotinib—TEK—connective tissue—chronic obstructive pulmonary disease	0.0014	0.00956	CbGeAlD
Nilotinib—EPHB4—bronchus—chronic obstructive pulmonary disease	0.00137	0.00934	CbGeAlD
Nilotinib—EPHA2—bronchus—chronic obstructive pulmonary disease	0.00135	0.00916	CbGeAlD
Nilotinib—EPHB4—smooth muscle tissue—chronic obstructive pulmonary disease	0.00134	0.00914	CbGeAlD
Nilotinib—MAP4K1—lung—chronic obstructive pulmonary disease	0.00134	0.00909	CbGeAlD
Nilotinib—CA12—respiratory system—chronic obstructive pulmonary disease	0.00133	0.00908	CbGeAlD
Nilotinib—TEK—bronchus—chronic obstructive pulmonary disease	0.00131	0.00894	CbGeAlD
Nilotinib—LCK—trachea—chronic obstructive pulmonary disease	0.00129	0.00881	CbGeAlD
Nilotinib—TEK—smooth muscle tissue—chronic obstructive pulmonary disease	0.00128	0.00874	CbGeAlD
Nilotinib—TIE1—lung—chronic obstructive pulmonary disease	0.00127	0.00868	CbGeAlD
Nilotinib—CSF1R—respiratory system—chronic obstructive pulmonary disease	0.00127	0.00866	CbGeAlD
Nilotinib—PDGFRA—connective tissue—chronic obstructive pulmonary disease	0.00127	0.00866	CbGeAlD
Nilotinib—EPHB6—bronchus—chronic obstructive pulmonary disease	0.00125	0.00854	CbGeAlD
Nilotinib—EPHB4—trachea—chronic obstructive pulmonary disease	0.00123	0.00838	CbGeAlD
Nilotinib—BRAF—lung—chronic obstructive pulmonary disease	0.00122	0.00832	CbGeAlD
Nilotinib—Imatinib—CYP1A2—chronic obstructive pulmonary disease	0.00121	0.634	CrCbGaD
Nilotinib—EPHB3—lung—chronic obstructive pulmonary disease	0.00121	0.00825	CbGeAlD
Nilotinib—EPHA2—trachea—chronic obstructive pulmonary disease	0.00121	0.00822	CbGeAlD
Nilotinib—CA12—connective tissue—chronic obstructive pulmonary disease	0.00117	0.00799	CbGeAlD
Nilotinib—PDGFRA—smooth muscle tissue—chronic obstructive pulmonary disease	0.00116	0.00792	CbGeAlD
Nilotinib—KIT—respiratory system—chronic obstructive pulmonary disease	0.00116	0.00786	CbGeAlD
Nilotinib—PDGFRB—respiratory system—chronic obstructive pulmonary disease	0.00113	0.00768	CbGeAlD
Nilotinib—EPHB6—trachea—chronic obstructive pulmonary disease	0.00113	0.00767	CbGeAlD
Nilotinib—CSF1R—connective tissue—chronic obstructive pulmonary disease	0.00112	0.00762	CbGeAlD
Nilotinib—HCK—lung—chronic obstructive pulmonary disease	0.00111	0.00758	CbGeAlD
Nilotinib—ABL2—lung—chronic obstructive pulmonary disease	0.00111	0.00754	CbGeAlD
Nilotinib—MAP2K5—bronchus—chronic obstructive pulmonary disease	0.00107	0.0073	CbGeAlD
Nilotinib—PDGFRA—trachea—chronic obstructive pulmonary disease	0.00107	0.00727	CbGeAlD
Nilotinib—CA1—respiratory system—chronic obstructive pulmonary disease	0.00106	0.00719	CbGeAlD
Nilotinib—CSF1R—bronchus—chronic obstructive pulmonary disease	0.00105	0.00713	CbGeAlD
Nilotinib—CSF1R—smooth muscle tissue—chronic obstructive pulmonary disease	0.00102	0.00697	CbGeAlD
Nilotinib—KIT—connective tissue—chronic obstructive pulmonary disease	0.00102	0.00692	CbGeAlD
Nilotinib—EPHA4—lung—chronic obstructive pulmonary disease	0.00101	0.00689	CbGeAlD
Nilotinib—ABL1—respiratory system—chronic obstructive pulmonary disease	0.00101	0.00685	CbGeAlD
Nilotinib—CA3—lung—chronic obstructive pulmonary disease	0.001	0.00681	CbGeAlD
Nilotinib—PDGFRB—connective tissue—chronic obstructive pulmonary disease	0.000993	0.00676	CbGeAlD
Nilotinib—CA12—trachea—chronic obstructive pulmonary disease	0.000986	0.00671	CbGeAlD
Nilotinib—MAP2K5—trachea—chronic obstructive pulmonary disease	0.000963	0.00656	CbGeAlD
Nilotinib—KIT—bronchus—chronic obstructive pulmonary disease	0.000951	0.00647	CbGeAlD
Nilotinib—CSF1R—trachea—chronic obstructive pulmonary disease	0.00094	0.0064	CbGeAlD
Nilotinib—MAPK14—lung—chronic obstructive pulmonary disease	0.000934	0.00635	CbGeAlD
Nilotinib—KIT—smooth muscle tissue—chronic obstructive pulmonary disease	0.00093	0.00633	CbGeAlD
Nilotinib—FGR—lung—chronic obstructive pulmonary disease	0.00093	0.00633	CbGeAlD
Nilotinib—LCK—lung—chronic obstructive pulmonary disease	0.00093	0.00633	CbGeAlD
Nilotinib—PDGFRB—bronchus—chronic obstructive pulmonary disease	0.000929	0.00632	CbGeAlD
Nilotinib—PDGFRB—smooth muscle tissue—chronic obstructive pulmonary disease	0.000909	0.00618	CbGeAlD
Nilotinib—ABL1—connective tissue—chronic obstructive pulmonary disease	0.000885	0.00603	CbGeAlD
Nilotinib—EPHB4—lung—chronic obstructive pulmonary disease	0.000885	0.00602	CbGeAlD
Nilotinib—EPHA2—lung—chronic obstructive pulmonary disease	0.000868	0.00591	CbGeAlD
Nilotinib—KIT—trachea—chronic obstructive pulmonary disease	0.000854	0.00581	CbGeAlD
Nilotinib—TEK—lung—chronic obstructive pulmonary disease	0.000847	0.00577	CbGeAlD
Nilotinib—PDGFRB—trachea—chronic obstructive pulmonary disease	0.000834	0.00568	CbGeAlD
Nilotinib—ABL1—bronchus—chronic obstructive pulmonary disease	0.000828	0.00563	CbGeAlD
Nilotinib—CA4—respiratory system—chronic obstructive pulmonary disease	0.000826	0.00562	CbGeAlD
Nilotinib—ABL1—smooth muscle tissue—chronic obstructive pulmonary disease	0.00081	0.00551	CbGeAlD
Nilotinib—EPHB6—lung—chronic obstructive pulmonary disease	0.000809	0.00551	CbGeAlD
Nilotinib—PDGFRA—lung—chronic obstructive pulmonary disease	0.000767	0.00522	CbGeAlD
Nilotinib—ABL1—trachea—chronic obstructive pulmonary disease	0.000743	0.00506	CbGeAlD
Nilotinib—CA12—lung—chronic obstructive pulmonary disease	0.000708	0.00482	CbGeAlD
Nilotinib—Imatinib—ALB—chronic obstructive pulmonary disease	0.000701	0.366	CrCbGaD
Nilotinib—MAP2K5—lung—chronic obstructive pulmonary disease	0.000692	0.00471	CbGeAlD
Nilotinib—CA2—respiratory system—chronic obstructive pulmonary disease	0.000685	0.00466	CbGeAlD
Nilotinib—CSF1R—lung—chronic obstructive pulmonary disease	0.000676	0.0046	CbGeAlD
Nilotinib—KIT—lung—chronic obstructive pulmonary disease	0.000613	0.00418	CbGeAlD
Nilotinib—CA4—trachea—chronic obstructive pulmonary disease	0.00061	0.00415	CbGeAlD
Nilotinib—CA2—connective tissue—chronic obstructive pulmonary disease	0.000603	0.0041	CbGeAlD
Nilotinib—PDGFRB—lung—chronic obstructive pulmonary disease	0.000599	0.00408	CbGeAlD
Nilotinib—CYP2B6—respiratory system—chronic obstructive pulmonary disease	0.000585	0.00398	CbGeAlD
Nilotinib—CA2—bronchus—chronic obstructive pulmonary disease	0.000564	0.00384	CbGeAlD
Nilotinib—CA1—lung—chronic obstructive pulmonary disease	0.000561	0.00382	CbGeAlD
Nilotinib—CA2—smooth muscle tissue—chronic obstructive pulmonary disease	0.000551	0.00375	CbGeAlD
Nilotinib—ABL1—lung—chronic obstructive pulmonary disease	0.000534	0.00363	CbGeAlD
Nilotinib—CA2—trachea—chronic obstructive pulmonary disease	0.000506	0.00344	CbGeAlD
Nilotinib—CYP2B6—bronchus—chronic obstructive pulmonary disease	0.000482	0.00328	CbGeAlD
Nilotinib—CA4—lung—chronic obstructive pulmonary disease	0.000439	0.00299	CbGeAlD
Nilotinib—CA2—lung—chronic obstructive pulmonary disease	0.000364	0.00248	CbGeAlD
Nilotinib—ABCG2—lung—chronic obstructive pulmonary disease	0.000337	0.00229	CbGeAlD
Nilotinib—ABCB1—respiratory system—chronic obstructive pulmonary disease	0.000313	0.00213	CbGeAlD
Nilotinib—CYP2B6—lung—chronic obstructive pulmonary disease	0.000311	0.00211	CbGeAlD
Nilotinib—Anxiety—Salbutamol—chronic obstructive pulmonary disease	0.000233	0.000794	CcSEcCtD
Nilotinib—Nervous system disorder—Formoterol—chronic obstructive pulmonary disease	0.000233	0.000793	CcSEcCtD
Nilotinib—Nervous system disorder—Arformoterol—chronic obstructive pulmonary disease	0.000233	0.000793	CcSEcCtD
Nilotinib—Abdominal pain—Tiotropium—chronic obstructive pulmonary disease	0.000232	0.000792	CcSEcCtD
Nilotinib—Oedema—Montelukast—chronic obstructive pulmonary disease	0.000232	0.000792	CcSEcCtD
Nilotinib—Tachycardia—Arformoterol—chronic obstructive pulmonary disease	0.000231	0.00079	CcSEcCtD
Nilotinib—Tachycardia—Formoterol—chronic obstructive pulmonary disease	0.000231	0.00079	CcSEcCtD
Nilotinib—ABCB1—trachea—chronic obstructive pulmonary disease	0.000231	0.00157	CbGeAlD
Nilotinib—Discomfort—Salbutamol—chronic obstructive pulmonary disease	0.000231	0.000787	CcSEcCtD
Nilotinib—Infection—Montelukast—chronic obstructive pulmonary disease	0.000231	0.000787	CcSEcCtD
Nilotinib—Muscular weakness—Prednisolone—chronic obstructive pulmonary disease	0.00023	0.000786	CcSEcCtD
Nilotinib—Skin disorder—Formoterol—chronic obstructive pulmonary disease	0.00023	0.000786	CcSEcCtD
Nilotinib—Skin disorder—Arformoterol—chronic obstructive pulmonary disease	0.00023	0.000786	CcSEcCtD
Nilotinib—Hypersensitivity—Aminophylline—chronic obstructive pulmonary disease	0.00023	0.000783	CcSEcCtD
Nilotinib—Dry mouth—Salbutamol—chronic obstructive pulmonary disease	0.000228	0.000779	CcSEcCtD
Nilotinib—Nervous system disorder—Montelukast—chronic obstructive pulmonary disease	0.000228	0.000777	CcSEcCtD
Nilotinib—Thrombocytopenia—Montelukast—chronic obstructive pulmonary disease	0.000227	0.000776	CcSEcCtD
Nilotinib—Abdominal distension—Prednisolone—chronic obstructive pulmonary disease	0.000227	0.000776	CcSEcCtD
Nilotinib—Sepsis—Prednisone—chronic obstructive pulmonary disease	0.000227	0.000774	CcSEcCtD
Nilotinib—Skin disorder—Montelukast—chronic obstructive pulmonary disease	0.000226	0.00077	CcSEcCtD
Nilotinib—Oedema—Salbutamol—chronic obstructive pulmonary disease	0.000224	0.000764	CcSEcCtD
Nilotinib—Infection—Salbutamol—chronic obstructive pulmonary disease	0.000222	0.000759	CcSEcCtD
Nilotinib—Hypotension—Formoterol—chronic obstructive pulmonary disease	0.000222	0.000756	CcSEcCtD
Nilotinib—Hypotension—Arformoterol—chronic obstructive pulmonary disease	0.000222	0.000756	CcSEcCtD
Nilotinib—Pancreatitis—Prednisolone—chronic obstructive pulmonary disease	0.000221	0.000755	CcSEcCtD
Nilotinib—Pruritus—Aminophylline—chronic obstructive pulmonary disease	0.00022	0.000752	CcSEcCtD
Nilotinib—Shock—Salbutamol—chronic obstructive pulmonary disease	0.00022	0.000752	CcSEcCtD
Nilotinib—Nervous system disorder—Salbutamol—chronic obstructive pulmonary disease	0.00022	0.000749	CcSEcCtD
Nilotinib—Tachycardia—Salbutamol—chronic obstructive pulmonary disease	0.000219	0.000746	CcSEcCtD
Nilotinib—Diabetes mellitus—Prednisone—chronic obstructive pulmonary disease	0.000218	0.000745	CcSEcCtD
Nilotinib—Skin disorder—Salbutamol—chronic obstructive pulmonary disease	0.000217	0.000742	CcSEcCtD
Nilotinib—Hypersensitivity—Tiotropium—chronic obstructive pulmonary disease	0.000216	0.000739	CcSEcCtD
Nilotinib—Hyperhidrosis—Salbutamol—chronic obstructive pulmonary disease	0.000216	0.000739	CcSEcCtD
Nilotinib—Musculoskeletal discomfort—Arformoterol—chronic obstructive pulmonary disease	0.000216	0.000737	CcSEcCtD
Nilotinib—Musculoskeletal discomfort—Formoterol—chronic obstructive pulmonary disease	0.000216	0.000737	CcSEcCtD
Nilotinib—Insomnia—Arformoterol—chronic obstructive pulmonary disease	0.000214	0.000732	CcSEcCtD
Nilotinib—Insomnia—Formoterol—chronic obstructive pulmonary disease	0.000214	0.000732	CcSEcCtD
Nilotinib—Anorexia—Salbutamol—chronic obstructive pulmonary disease	0.000213	0.000728	CcSEcCtD
Nilotinib—Diarrhoea—Aminophylline—chronic obstructive pulmonary disease	0.000213	0.000727	CcSEcCtD
Nilotinib—Musculoskeletal discomfort—Montelukast—chronic obstructive pulmonary disease	0.000212	0.000722	CcSEcCtD
Nilotinib—Dyspnoea—Formoterol—chronic obstructive pulmonary disease	0.000211	0.000721	CcSEcCtD
Nilotinib—Dyspnoea—Arformoterol—chronic obstructive pulmonary disease	0.000211	0.000721	CcSEcCtD
Nilotinib—Insomnia—Montelukast—chronic obstructive pulmonary disease	0.00021	0.000717	CcSEcCtD
Nilotinib—Hypotension—Salbutamol—chronic obstructive pulmonary disease	0.000209	0.000714	CcSEcCtD
Nilotinib—Dyspepsia—Arformoterol—chronic obstructive pulmonary disease	0.000209	0.000712	CcSEcCtD
Nilotinib—Dyspepsia—Formoterol—chronic obstructive pulmonary disease	0.000209	0.000712	CcSEcCtD
Nilotinib—Paraesthesia—Montelukast—chronic obstructive pulmonary disease	0.000209	0.000712	CcSEcCtD
Nilotinib—Pruritus—Tiotropium—chronic obstructive pulmonary disease	0.000208	0.000709	CcSEcCtD
Nilotinib—Dizziness—Aminophylline—chronic obstructive pulmonary disease	0.000206	0.000703	CcSEcCtD
Nilotinib—Weight increased—Prednisolone—chronic obstructive pulmonary disease	0.000206	0.000701	CcSEcCtD
Nilotinib—Gastrointestinal disorder—Formoterol—chronic obstructive pulmonary disease	0.000205	0.000698	CcSEcCtD
Nilotinib—Gastrointestinal disorder—Arformoterol—chronic obstructive pulmonary disease	0.000205	0.000698	CcSEcCtD
Nilotinib—Dyspepsia—Montelukast—chronic obstructive pulmonary disease	0.000204	0.000698	CcSEcCtD
Nilotinib—Fatigue—Formoterol—chronic obstructive pulmonary disease	0.000204	0.000698	CcSEcCtD
Nilotinib—Fatigue—Arformoterol—chronic obstructive pulmonary disease	0.000204	0.000698	CcSEcCtD
Nilotinib—Musculoskeletal discomfort—Salbutamol—chronic obstructive pulmonary disease	0.000204	0.000696	CcSEcCtD
Nilotinib—Pain—Formoterol—chronic obstructive pulmonary disease	0.000203	0.000692	CcSEcCtD
Nilotinib—Constipation—Arformoterol—chronic obstructive pulmonary disease	0.000203	0.000692	CcSEcCtD
Nilotinib—Constipation—Formoterol—chronic obstructive pulmonary disease	0.000203	0.000692	CcSEcCtD
Nilotinib—Pain—Arformoterol—chronic obstructive pulmonary disease	0.000203	0.000692	CcSEcCtD
Nilotinib—Insomnia—Salbutamol—chronic obstructive pulmonary disease	0.000203	0.000691	CcSEcCtD
Nilotinib—Amnesia—Prednisone—chronic obstructive pulmonary disease	0.000202	0.00069	CcSEcCtD
Nilotinib—Increased appetite—Prednisone—chronic obstructive pulmonary disease	0.000202	0.00069	CcSEcCtD
Nilotinib—Paraesthesia—Salbutamol—chronic obstructive pulmonary disease	0.000201	0.000686	CcSEcCtD
Nilotinib—Gastrointestinal disorder—Montelukast—chronic obstructive pulmonary disease	0.000201	0.000684	CcSEcCtD
Nilotinib—Fatigue—Montelukast—chronic obstructive pulmonary disease	0.0002	0.000683	CcSEcCtD
Nilotinib—Dyspnoea—Salbutamol—chronic obstructive pulmonary disease	0.0002	0.000681	CcSEcCtD
Nilotinib—Pain—Montelukast—chronic obstructive pulmonary disease	0.000199	0.000678	CcSEcCtD
Nilotinib—Acute coronary syndrome—Prednisolone—chronic obstructive pulmonary disease	0.000198	0.000677	CcSEcCtD
Nilotinib—Vomiting—Aminophylline—chronic obstructive pulmonary disease	0.000198	0.000676	CcSEcCtD
Nilotinib—Myocardial infarction—Prednisolone—chronic obstructive pulmonary disease	0.000197	0.000673	CcSEcCtD
Nilotinib—Neuropathy peripheral—Prednisolone—chronic obstructive pulmonary disease	0.000197	0.000673	CcSEcCtD
Nilotinib—Dyspepsia—Salbutamol—chronic obstructive pulmonary disease	0.000197	0.000672	CcSEcCtD
Nilotinib—Rash—Aminophylline—chronic obstructive pulmonary disease	0.000196	0.00067	CcSEcCtD
Nilotinib—Dermatitis—Aminophylline—chronic obstructive pulmonary disease	0.000196	0.00067	CcSEcCtD
Nilotinib—Conjunctivitis—Prednisolone—chronic obstructive pulmonary disease	0.000196	0.000668	CcSEcCtD
Nilotinib—Feeling abnormal—Formoterol—chronic obstructive pulmonary disease	0.000195	0.000667	CcSEcCtD
Nilotinib—Feeling abnormal—Arformoterol—chronic obstructive pulmonary disease	0.000195	0.000667	CcSEcCtD
Nilotinib—Headache—Aminophylline—chronic obstructive pulmonary disease	0.000195	0.000666	CcSEcCtD
Nilotinib—Decreased appetite—Salbutamol—chronic obstructive pulmonary disease	0.000195	0.000664	CcSEcCtD
Nilotinib—Cardiac failure—Prednisone—chronic obstructive pulmonary disease	0.000195	0.000664	CcSEcCtD
Nilotinib—Dizziness—Tiotropium—chronic obstructive pulmonary disease	0.000194	0.000663	CcSEcCtD
Nilotinib—Gastrointestinal pain—Arformoterol—chronic obstructive pulmonary disease	0.000194	0.000662	CcSEcCtD
Nilotinib—Gastrointestinal pain—Formoterol—chronic obstructive pulmonary disease	0.000194	0.000662	CcSEcCtD
Nilotinib—Lethargy—Prednisone—chronic obstructive pulmonary disease	0.000194	0.000661	CcSEcCtD
Nilotinib—Gastrointestinal disorder—Salbutamol—chronic obstructive pulmonary disease	0.000193	0.00066	CcSEcCtD
Nilotinib—Fatigue—Salbutamol—chronic obstructive pulmonary disease	0.000193	0.000659	CcSEcCtD
Nilotinib—Pain—Salbutamol—chronic obstructive pulmonary disease	0.000191	0.000653	CcSEcCtD
Nilotinib—Constipation—Salbutamol—chronic obstructive pulmonary disease	0.000191	0.000653	CcSEcCtD
Nilotinib—Gastrointestinal pain—Montelukast—chronic obstructive pulmonary disease	0.00019	0.000648	CcSEcCtD
Nilotinib—Gastrointestinal haemorrhage—Prednisone—chronic obstructive pulmonary disease	0.00019	0.000648	CcSEcCtD
Nilotinib—Urticaria—Formoterol—chronic obstructive pulmonary disease	0.000188	0.000643	CcSEcCtD
Nilotinib—Urticaria—Arformoterol—chronic obstructive pulmonary disease	0.000188	0.000643	CcSEcCtD
Nilotinib—Abdominal pain—Arformoterol—chronic obstructive pulmonary disease	0.000187	0.00064	CcSEcCtD
Nilotinib—Abdominal pain—Formoterol—chronic obstructive pulmonary disease	0.000187	0.00064	CcSEcCtD
Nilotinib—Body temperature increased—Formoterol—chronic obstructive pulmonary disease	0.000187	0.00064	CcSEcCtD
Nilotinib—Body temperature increased—Arformoterol—chronic obstructive pulmonary disease	0.000187	0.00064	CcSEcCtD
Nilotinib—Vomiting—Tiotropium—chronic obstructive pulmonary disease	0.000187	0.000637	CcSEcCtD
Nilotinib—Rash—Tiotropium—chronic obstructive pulmonary disease	0.000185	0.000632	CcSEcCtD
Nilotinib—Dermatitis—Tiotropium—chronic obstructive pulmonary disease	0.000185	0.000632	CcSEcCtD
Nilotinib—Nausea—Aminophylline—chronic obstructive pulmonary disease	0.000185	0.000631	CcSEcCtD
Nilotinib—Urticaria—Montelukast—chronic obstructive pulmonary disease	0.000185	0.00063	CcSEcCtD
Nilotinib—Feeling abnormal—Salbutamol—chronic obstructive pulmonary disease	0.000184	0.00063	CcSEcCtD
Nilotinib—Headache—Tiotropium—chronic obstructive pulmonary disease	0.000184	0.000628	CcSEcCtD
Nilotinib—Bradycardia—Prednisolone—chronic obstructive pulmonary disease	0.000184	0.000628	CcSEcCtD
Nilotinib—Abdominal pain—Montelukast—chronic obstructive pulmonary disease	0.000184	0.000626	CcSEcCtD
Nilotinib—Body temperature increased—Montelukast—chronic obstructive pulmonary disease	0.000184	0.000626	CcSEcCtD
Nilotinib—Face oedema—Prednisone—chronic obstructive pulmonary disease	0.000183	0.000625	CcSEcCtD
Nilotinib—Gastrointestinal pain—Salbutamol—chronic obstructive pulmonary disease	0.000183	0.000625	CcSEcCtD
Nilotinib—Haemoglobin—Prednisolone—chronic obstructive pulmonary disease	0.000182	0.00062	CcSEcCtD
Nilotinib—Haemorrhage—Prednisolone—chronic obstructive pulmonary disease	0.000181	0.000617	CcSEcCtD
Nilotinib—Urticaria—Salbutamol—chronic obstructive pulmonary disease	0.000178	0.000607	CcSEcCtD
Nilotinib—Abdominal pain—Salbutamol—chronic obstructive pulmonary disease	0.000177	0.000604	CcSEcCtD
Nilotinib—Body temperature increased—Salbutamol—chronic obstructive pulmonary disease	0.000177	0.000604	CcSEcCtD
Nilotinib—Hypersensitivity—Arformoterol—chronic obstructive pulmonary disease	0.000175	0.000596	CcSEcCtD
Nilotinib—Hypersensitivity—Formoterol—chronic obstructive pulmonary disease	0.000175	0.000596	CcSEcCtD
Nilotinib—Nausea—Tiotropium—chronic obstructive pulmonary disease	0.000175	0.000595	CcSEcCtD
Nilotinib—Visual impairment—Prednisolone—chronic obstructive pulmonary disease	0.000174	0.000594	CcSEcCtD
Nilotinib—Dry skin—Prednisone—chronic obstructive pulmonary disease	0.000174	0.000594	CcSEcCtD
Nilotinib—Hypokalaemia—Prednisone—chronic obstructive pulmonary disease	0.000173	0.00059	CcSEcCtD
Nilotinib—Hypersensitivity—Montelukast—chronic obstructive pulmonary disease	0.000171	0.000584	CcSEcCtD
Nilotinib—Asthenia—Formoterol—chronic obstructive pulmonary disease	0.00017	0.00058	CcSEcCtD
Nilotinib—Asthenia—Arformoterol—chronic obstructive pulmonary disease	0.00017	0.00058	CcSEcCtD
Nilotinib—Pruritus—Formoterol—chronic obstructive pulmonary disease	0.000168	0.000572	CcSEcCtD
Nilotinib—Pruritus—Arformoterol—chronic obstructive pulmonary disease	0.000168	0.000572	CcSEcCtD
Nilotinib—Alanine aminotransferase increased—Prednisone—chronic obstructive pulmonary disease	0.000167	0.000571	CcSEcCtD
Nilotinib—Muscular weakness—Prednisone—chronic obstructive pulmonary disease	0.000167	0.000571	CcSEcCtD
Nilotinib—Asthenia—Montelukast—chronic obstructive pulmonary disease	0.000167	0.000569	CcSEcCtD
Nilotinib—ABCB1—lung—chronic obstructive pulmonary disease	0.000166	0.00113	CbGeAlD
Nilotinib—Abdominal distension—Prednisone—chronic obstructive pulmonary disease	0.000165	0.000564	CcSEcCtD
Nilotinib—Hypersensitivity—Salbutamol—chronic obstructive pulmonary disease	0.000165	0.000563	CcSEcCtD
Nilotinib—Pruritus—Montelukast—chronic obstructive pulmonary disease	0.000164	0.000561	CcSEcCtD
Nilotinib—Diarrhoea—Arformoterol—chronic obstructive pulmonary disease	0.000162	0.000554	CcSEcCtD
Nilotinib—Diarrhoea—Formoterol—chronic obstructive pulmonary disease	0.000162	0.000554	CcSEcCtD
Nilotinib—Arrhythmia—Prednisolone—chronic obstructive pulmonary disease	0.000161	0.000551	CcSEcCtD
Nilotinib—Pancreatitis—Prednisone—chronic obstructive pulmonary disease	0.000161	0.000549	CcSEcCtD
Nilotinib—Asthenia—Salbutamol—chronic obstructive pulmonary disease	0.000161	0.000548	CcSEcCtD
Nilotinib—Diarrhoea—Montelukast—chronic obstructive pulmonary disease	0.000159	0.000542	CcSEcCtD
Nilotinib—Pruritus—Salbutamol—chronic obstructive pulmonary disease	0.000158	0.00054	CcSEcCtD
Nilotinib—Erythema—Prednisolone—chronic obstructive pulmonary disease	0.000157	0.000537	CcSEcCtD
Nilotinib—Dizziness—Formoterol—chronic obstructive pulmonary disease	0.000157	0.000535	CcSEcCtD
Nilotinib—Dizziness—Arformoterol—chronic obstructive pulmonary disease	0.000157	0.000535	CcSEcCtD
Nilotinib—Dizziness—Montelukast—chronic obstructive pulmonary disease	0.000154	0.000524	CcSEcCtD
Nilotinib—Neutropenia—Prednisone—chronic obstructive pulmonary disease	0.000153	0.000524	CcSEcCtD
Nilotinib—Diarrhoea—Salbutamol—chronic obstructive pulmonary disease	0.000153	0.000523	CcSEcCtD
Nilotinib—Erectile dysfunction—Prednisone—chronic obstructive pulmonary disease	0.000151	0.000516	CcSEcCtD
Nilotinib—Vomiting—Formoterol—chronic obstructive pulmonary disease	0.000151	0.000514	CcSEcCtD
Nilotinib—Vomiting—Arformoterol—chronic obstructive pulmonary disease	0.000151	0.000514	CcSEcCtD
Nilotinib—Rash—Formoterol—chronic obstructive pulmonary disease	0.00015	0.00051	CcSEcCtD
Nilotinib—Rash—Arformoterol—chronic obstructive pulmonary disease	0.00015	0.00051	CcSEcCtD
Nilotinib—Dermatitis—Arformoterol—chronic obstructive pulmonary disease	0.000149	0.00051	CcSEcCtD
Nilotinib—Dermatitis—Formoterol—chronic obstructive pulmonary disease	0.000149	0.00051	CcSEcCtD
Nilotinib—Weight increased—Prednisone—chronic obstructive pulmonary disease	0.000149	0.00051	CcSEcCtD
Nilotinib—Headache—Arformoterol—chronic obstructive pulmonary disease	0.000149	0.000507	CcSEcCtD
Nilotinib—Headache—Formoterol—chronic obstructive pulmonary disease	0.000149	0.000507	CcSEcCtD
Nilotinib—Weight decreased—Prednisone—chronic obstructive pulmonary disease	0.000148	0.000507	CcSEcCtD
Nilotinib—Vision blurred—Prednisolone—chronic obstructive pulmonary disease	0.000148	0.000506	CcSEcCtD
Nilotinib—Dizziness—Salbutamol—chronic obstructive pulmonary disease	0.000148	0.000505	CcSEcCtD
Nilotinib—Hyperglycaemia—Prednisone—chronic obstructive pulmonary disease	0.000148	0.000505	CcSEcCtD
Nilotinib—Vomiting—Montelukast—chronic obstructive pulmonary disease	0.000148	0.000504	CcSEcCtD
Nilotinib—Rash—Montelukast—chronic obstructive pulmonary disease	0.000146	0.0005	CcSEcCtD
Nilotinib—Dermatitis—Montelukast—chronic obstructive pulmonary disease	0.000146	0.000499	CcSEcCtD
Nilotinib—Ill-defined disorder—Prednisolone—chronic obstructive pulmonary disease	0.000146	0.000498	CcSEcCtD
Nilotinib—Headache—Montelukast—chronic obstructive pulmonary disease	0.000145	0.000496	CcSEcCtD
Nilotinib—Acute coronary syndrome—Prednisone—chronic obstructive pulmonary disease	0.000144	0.000492	CcSEcCtD
Nilotinib—Neuropathy peripheral—Prednisone—chronic obstructive pulmonary disease	0.000143	0.000489	CcSEcCtD
Nilotinib—Myocardial infarction—Prednisone—chronic obstructive pulmonary disease	0.000143	0.000489	CcSEcCtD
Nilotinib—Vomiting—Salbutamol—chronic obstructive pulmonary disease	0.000142	0.000486	CcSEcCtD
Nilotinib—Malaise—Prednisolone—chronic obstructive pulmonary disease	0.000142	0.000484	CcSEcCtD
Nilotinib—Vertigo—Prednisolone—chronic obstructive pulmonary disease	0.000141	0.000482	CcSEcCtD
Nilotinib—Rash—Salbutamol—chronic obstructive pulmonary disease	0.000141	0.000482	CcSEcCtD
Nilotinib—Syncope—Prednisolone—chronic obstructive pulmonary disease	0.000141	0.000481	CcSEcCtD
Nilotinib—Dermatitis—Salbutamol—chronic obstructive pulmonary disease	0.000141	0.000481	CcSEcCtD
Nilotinib—Nausea—Arformoterol—chronic obstructive pulmonary disease	0.000141	0.000481	CcSEcCtD
Nilotinib—Nausea—Formoterol—chronic obstructive pulmonary disease	0.000141	0.000481	CcSEcCtD
Nilotinib—Headache—Salbutamol—chronic obstructive pulmonary disease	0.00014	0.000479	CcSEcCtD
Nilotinib—Loss of consciousness—Prednisolone—chronic obstructive pulmonary disease	0.000138	0.000472	CcSEcCtD
Nilotinib—Nausea—Montelukast—chronic obstructive pulmonary disease	0.000138	0.000471	CcSEcCtD
Nilotinib—Hypertension—Prednisolone—chronic obstructive pulmonary disease	0.000136	0.000464	CcSEcCtD
Nilotinib—Bradycardia—Prednisone—chronic obstructive pulmonary disease	0.000134	0.000456	CcSEcCtD
Nilotinib—Nausea—Salbutamol—chronic obstructive pulmonary disease	0.000133	0.000454	CcSEcCtD
Nilotinib—Discomfort—Prednisolone—chronic obstructive pulmonary disease	0.000132	0.000452	CcSEcCtD
Nilotinib—Haemoglobin—Prednisone—chronic obstructive pulmonary disease	0.000132	0.00045	CcSEcCtD
Nilotinib—Haemorrhage—Prednisone—chronic obstructive pulmonary disease	0.000131	0.000448	CcSEcCtD
Nilotinib—Connective tissue disorder—Prednisone—chronic obstructive pulmonary disease	0.000129	0.00044	CcSEcCtD
Nilotinib—Oedema—Prednisolone—chronic obstructive pulmonary disease	0.000128	0.000438	CcSEcCtD
Nilotinib—Shock—Prednisolone—chronic obstructive pulmonary disease	0.000126	0.000431	CcSEcCtD
Nilotinib—Tachycardia—Prednisolone—chronic obstructive pulmonary disease	0.000125	0.000428	CcSEcCtD
Nilotinib—Hyperhidrosis—Prednisolone—chronic obstructive pulmonary disease	0.000124	0.000424	CcSEcCtD
Nilotinib—Eye disorder—Prednisone—chronic obstructive pulmonary disease	0.000123	0.000419	CcSEcCtD
Nilotinib—Flushing—Prednisone—chronic obstructive pulmonary disease	0.000122	0.000416	CcSEcCtD
Nilotinib—Angiopathy—Prednisone—chronic obstructive pulmonary disease	0.000119	0.000407	CcSEcCtD
Nilotinib—Immune system disorder—Prednisone—chronic obstructive pulmonary disease	0.000119	0.000405	CcSEcCtD
Nilotinib—Arrhythmia—Prednisone—chronic obstructive pulmonary disease	0.000117	0.0004	CcSEcCtD
Nilotinib—Insomnia—Prednisolone—chronic obstructive pulmonary disease	0.000116	0.000396	CcSEcCtD
Nilotinib—Alopecia—Prednisone—chronic obstructive pulmonary disease	0.000116	0.000396	CcSEcCtD
Nilotinib—Paraesthesia—Prednisolone—chronic obstructive pulmonary disease	0.000115	0.000393	CcSEcCtD
Nilotinib—Mental disorder—Prednisone—chronic obstructive pulmonary disease	0.000115	0.000393	CcSEcCtD
Nilotinib—Malnutrition—Prednisone—chronic obstructive pulmonary disease	0.000114	0.00039	CcSEcCtD
Nilotinib—Erythema—Prednisone—chronic obstructive pulmonary disease	0.000114	0.00039	CcSEcCtD
Nilotinib—Pain—Prednisolone—chronic obstructive pulmonary disease	0.00011	0.000375	CcSEcCtD
Nilotinib—Vision blurred—Prednisone—chronic obstructive pulmonary disease	0.000108	0.000368	CcSEcCtD
Nilotinib—Ill-defined disorder—Prednisone—chronic obstructive pulmonary disease	0.000106	0.000362	CcSEcCtD
Nilotinib—Feeling abnormal—Prednisolone—chronic obstructive pulmonary disease	0.000106	0.000361	CcSEcCtD
Nilotinib—Anaemia—Prednisone—chronic obstructive pulmonary disease	0.000106	0.000361	CcSEcCtD
Nilotinib—Malaise—Prednisone—chronic obstructive pulmonary disease	0.000103	0.000352	CcSEcCtD
Nilotinib—Vertigo—Prednisone—chronic obstructive pulmonary disease	0.000103	0.000351	CcSEcCtD
Nilotinib—Syncope—Prednisone—chronic obstructive pulmonary disease	0.000103	0.00035	CcSEcCtD
Nilotinib—Urticaria—Prednisolone—chronic obstructive pulmonary disease	0.000102	0.000348	CcSEcCtD
Nilotinib—Loss of consciousness—Prednisone—chronic obstructive pulmonary disease	0.0001	0.000343	CcSEcCtD
Nilotinib—Hypertension—Prednisone—chronic obstructive pulmonary disease	9.87e-05	0.000337	CcSEcCtD
Nilotinib—Arthralgia—Prednisone—chronic obstructive pulmonary disease	9.73e-05	0.000332	CcSEcCtD
Nilotinib—Myalgia—Prednisone—chronic obstructive pulmonary disease	9.73e-05	0.000332	CcSEcCtD
Nilotinib—Anxiety—Prednisone—chronic obstructive pulmonary disease	9.7e-05	0.000331	CcSEcCtD
Nilotinib—Unspecified disorder of skin and subcutaneous tissue—Prednisone—chronic obstructive pulmonary disease	9.67e-05	0.00033	CcSEcCtD
Nilotinib—Discomfort—Prednisone—chronic obstructive pulmonary disease	9.62e-05	0.000328	CcSEcCtD
Nilotinib—Hypersensitivity—Prednisolone—chronic obstructive pulmonary disease	9.46e-05	0.000323	CcSEcCtD
Nilotinib—Oedema—Prednisone—chronic obstructive pulmonary disease	9.33e-05	0.000318	CcSEcCtD
Nilotinib—Infection—Prednisone—chronic obstructive pulmonary disease	9.27e-05	0.000316	CcSEcCtD
Nilotinib—Shock—Prednisone—chronic obstructive pulmonary disease	9.18e-05	0.000313	CcSEcCtD
Nilotinib—Nervous system disorder—Prednisone—chronic obstructive pulmonary disease	9.15e-05	0.000312	CcSEcCtD
Nilotinib—Tachycardia—Prednisone—chronic obstructive pulmonary disease	9.11e-05	0.000311	CcSEcCtD
Nilotinib—Skin disorder—Prednisone—chronic obstructive pulmonary disease	9.06e-05	0.000309	CcSEcCtD
Nilotinib—Hyperhidrosis—Prednisone—chronic obstructive pulmonary disease	9.02e-05	0.000308	CcSEcCtD
Nilotinib—Anorexia—Prednisone—chronic obstructive pulmonary disease	8.89e-05	0.000303	CcSEcCtD
Nilotinib—Musculoskeletal discomfort—Prednisone—chronic obstructive pulmonary disease	8.5e-05	0.00029	CcSEcCtD
Nilotinib—Dizziness—Prednisolone—chronic obstructive pulmonary disease	8.49e-05	0.00029	CcSEcCtD
Nilotinib—Insomnia—Prednisone—chronic obstructive pulmonary disease	8.44e-05	0.000288	CcSEcCtD
Nilotinib—Paraesthesia—Prednisone—chronic obstructive pulmonary disease	8.38e-05	0.000286	CcSEcCtD
Nilotinib—Dyspepsia—Prednisone—chronic obstructive pulmonary disease	8.21e-05	0.00028	CcSEcCtD
Nilotinib—Decreased appetite—Prednisone—chronic obstructive pulmonary disease	8.11e-05	0.000277	CcSEcCtD
Nilotinib—Rash—Prednisolone—chronic obstructive pulmonary disease	8.1e-05	0.000276	CcSEcCtD
Nilotinib—Dermatitis—Prednisolone—chronic obstructive pulmonary disease	8.09e-05	0.000276	CcSEcCtD
Nilotinib—Fatigue—Prednisone—chronic obstructive pulmonary disease	8.05e-05	0.000275	CcSEcCtD
Nilotinib—Headache—Prednisolone—chronic obstructive pulmonary disease	8.04e-05	0.000274	CcSEcCtD
Nilotinib—Constipation—Prednisone—chronic obstructive pulmonary disease	7.98e-05	0.000272	CcSEcCtD
Nilotinib—Feeling abnormal—Prednisone—chronic obstructive pulmonary disease	7.69e-05	0.000262	CcSEcCtD
Nilotinib—Gastrointestinal pain—Prednisone—chronic obstructive pulmonary disease	7.63e-05	0.00026	CcSEcCtD
Nilotinib—Nausea—Prednisolone—chronic obstructive pulmonary disease	7.63e-05	0.00026	CcSEcCtD
Nilotinib—Urticaria—Prednisone—chronic obstructive pulmonary disease	7.41e-05	0.000253	CcSEcCtD
Nilotinib—Body temperature increased—Prednisone—chronic obstructive pulmonary disease	7.38e-05	0.000252	CcSEcCtD
Nilotinib—Abdominal pain—Prednisone—chronic obstructive pulmonary disease	7.38e-05	0.000252	CcSEcCtD
Nilotinib—Hypersensitivity—Prednisone—chronic obstructive pulmonary disease	6.88e-05	0.000235	CcSEcCtD
Nilotinib—Asthenia—Prednisone—chronic obstructive pulmonary disease	6.7e-05	0.000228	CcSEcCtD
Nilotinib—Pruritus—Prednisone—chronic obstructive pulmonary disease	6.6e-05	0.000225	CcSEcCtD
Nilotinib—Diarrhoea—Prednisone—chronic obstructive pulmonary disease	6.38e-05	0.000218	CcSEcCtD
Nilotinib—Dizziness—Prednisone—chronic obstructive pulmonary disease	6.17e-05	0.000211	CcSEcCtD
Nilotinib—Vomiting—Prednisone—chronic obstructive pulmonary disease	5.93e-05	0.000202	CcSEcCtD
Nilotinib—Rash—Prednisone—chronic obstructive pulmonary disease	5.88e-05	0.000201	CcSEcCtD
Nilotinib—Dermatitis—Prednisone—chronic obstructive pulmonary disease	5.88e-05	0.000201	CcSEcCtD
Nilotinib—Headache—Prednisone—chronic obstructive pulmonary disease	5.85e-05	0.000199	CcSEcCtD
Nilotinib—Nausea—Prednisone—chronic obstructive pulmonary disease	5.54e-05	0.000189	CcSEcCtD
Nilotinib—LCK—Immune System—TLR4—chronic obstructive pulmonary disease	1.06e-05	4.67e-05	CbGpPWpGaD
Nilotinib—CYP2C9—Metabolism of lipids and lipoproteins—CYP1A1—chronic obstructive pulmonary disease	1.05e-05	4.67e-05	CbGpPWpGaD
Nilotinib—ABCG2—Metabolism—HMOX1—chronic obstructive pulmonary disease	1.05e-05	4.66e-05	CbGpPWpGaD
Nilotinib—LYN—Adaptive Immune System—EGFR—chronic obstructive pulmonary disease	1.05e-05	4.66e-05	CbGpPWpGaD
Nilotinib—LYN—Signaling Pathways—EDN1—chronic obstructive pulmonary disease	1.04e-05	4.62e-05	CbGpPWpGaD
Nilotinib—MAPK14—Innate Immune System—EGFR—chronic obstructive pulmonary disease	1.04e-05	4.6e-05	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—KL—chronic obstructive pulmonary disease	1.04e-05	4.59e-05	CbGpPWpGaD
Nilotinib—PDGFRA—Signaling Pathways—HTR2A—chronic obstructive pulmonary disease	1.04e-05	4.58e-05	CbGpPWpGaD
Nilotinib—PDGFRA—Disease—NOS3—chronic obstructive pulmonary disease	1.03e-05	4.56e-05	CbGpPWpGaD
Nilotinib—LYN—Hemostasis—TP53—chronic obstructive pulmonary disease	1.02e-05	4.52e-05	CbGpPWpGaD
Nilotinib—CYP2B6—Metabolism—CTGF—chronic obstructive pulmonary disease	1.02e-05	4.5e-05	CbGpPWpGaD
Nilotinib—LCK—Hemostasis—TGFB1—chronic obstructive pulmonary disease	1.02e-05	4.5e-05	CbGpPWpGaD
Nilotinib—KIT—Signaling Pathways—LEP—chronic obstructive pulmonary disease	1.02e-05	4.5e-05	CbGpPWpGaD
Nilotinib—ABL1—Hemostasis—TP53—chronic obstructive pulmonary disease	1.02e-05	4.5e-05	CbGpPWpGaD
Nilotinib—MAP2K5—Signaling Pathways—NOS3—chronic obstructive pulmonary disease	1.01e-05	4.46e-05	CbGpPWpGaD
Nilotinib—KIT—Innate Immune System—IL6—chronic obstructive pulmonary disease	1.01e-05	4.46e-05	CbGpPWpGaD
Nilotinib—KIT—Immune System—IL1B—chronic obstructive pulmonary disease	1e-05	4.44e-05	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—EDN1—chronic obstructive pulmonary disease	9.91e-06	4.38e-05	CbGpPWpGaD
Nilotinib—ABCG2—Metabolism—GSTM1—chronic obstructive pulmonary disease	9.81e-06	4.34e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Disease—SERPINE1—chronic obstructive pulmonary disease	9.73e-06	4.3e-05	CbGpPWpGaD
Nilotinib—MAPK14—Gene Expression—SERPINE1—chronic obstructive pulmonary disease	9.72e-06	4.3e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling Pathways—ERBB3—chronic obstructive pulmonary disease	9.7e-06	4.29e-05	CbGpPWpGaD
Nilotinib—MAPK14—Hemostasis—TP53—chronic obstructive pulmonary disease	9.69e-06	4.29e-05	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—RAPGEF3—chronic obstructive pulmonary disease	9.65e-06	4.27e-05	CbGpPWpGaD
Nilotinib—PDGFRA—Signaling Pathways—LEP—chronic obstructive pulmonary disease	9.63e-06	4.26e-05	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—ADRB2—chronic obstructive pulmonary disease	9.58e-06	4.24e-05	CbGpPWpGaD
Nilotinib—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—chronic obstructive pulmonary disease	9.57e-06	4.23e-05	CbGpPWpGaD
Nilotinib—CYP2C8—Metabolism—GSTT1—chronic obstructive pulmonary disease	9.56e-06	4.23e-05	CbGpPWpGaD
Nilotinib—PDGFRA—Innate Immune System—IL6—chronic obstructive pulmonary disease	9.55e-06	4.23e-05	CbGpPWpGaD
Nilotinib—LYN—Developmental Biology—IL6—chronic obstructive pulmonary disease	9.54e-06	4.22e-05	CbGpPWpGaD
Nilotinib—PDGFRA—Immune System—IL1B—chronic obstructive pulmonary disease	9.5e-06	4.2e-05	CbGpPWpGaD
Nilotinib—LYN—Signaling Pathways—ERBB3—chronic obstructive pulmonary disease	9.5e-06	4.2e-05	CbGpPWpGaD
Nilotinib—ABL1—Developmental Biology—IL6—chronic obstructive pulmonary disease	9.49e-06	4.2e-05	CbGpPWpGaD
Nilotinib—CYP2C8—Metabolism—GCLC—chronic obstructive pulmonary disease	9.45e-06	4.18e-05	CbGpPWpGaD
Nilotinib—MAPK8—Signaling Pathways—CXCL8—chronic obstructive pulmonary disease	9.41e-06	4.16e-05	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—GC—chronic obstructive pulmonary disease	9.39e-06	4.15e-05	CbGpPWpGaD
Nilotinib—CYP2B6—Metabolism—CYP1A2—chronic obstructive pulmonary disease	9.38e-06	4.15e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling Pathways—HTR2A—chronic obstructive pulmonary disease	9.34e-06	4.13e-05	CbGpPWpGaD
Nilotinib—ABCG2—Metabolism—CYP1A1—chronic obstructive pulmonary disease	9.3e-06	4.11e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Disease—NOS3—chronic obstructive pulmonary disease	9.29e-06	4.11e-05	CbGpPWpGaD
Nilotinib—LCK—Disease—NOS2—chronic obstructive pulmonary disease	9.27e-06	4.1e-05	CbGpPWpGaD
Nilotinib—LYN—Signaling Pathways—HTR2A—chronic obstructive pulmonary disease	9.14e-06	4.04e-05	CbGpPWpGaD
Nilotinib—MAPK14—Developmental Biology—IL6—chronic obstructive pulmonary disease	9.04e-06	4e-05	CbGpPWpGaD
Nilotinib—HCK—Immune System—IL6—chronic obstructive pulmonary disease	9.03e-06	3.99e-05	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—ERBB3—chronic obstructive pulmonary disease	9e-06	3.98e-05	CbGpPWpGaD
Nilotinib—LCK—Innate Immune System—EGFR—chronic obstructive pulmonary disease	8.98e-06	3.97e-05	CbGpPWpGaD
Nilotinib—MAP2K5—Signaling Pathways—CXCL8—chronic obstructive pulmonary disease	8.95e-06	3.96e-05	CbGpPWpGaD
Nilotinib—MAPK11—Signaling Pathways—SERPINE1—chronic obstructive pulmonary disease	8.86e-06	3.92e-05	CbGpPWpGaD
Nilotinib—CYP2C8—Metabolism of lipids and lipoproteins—ALB—chronic obstructive pulmonary disease	8.81e-06	3.9e-05	CbGpPWpGaD
Nilotinib—BRAF—Signaling Pathways—SERPINE1—chronic obstructive pulmonary disease	8.77e-06	3.88e-05	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—ALDH7A1—chronic obstructive pulmonary disease	8.73e-06	3.86e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling Pathways—LEP—chronic obstructive pulmonary disease	8.68e-06	3.84e-05	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—HTR2A—chronic obstructive pulmonary disease	8.67e-06	3.83e-05	CbGpPWpGaD
Nilotinib—LCK—Adaptive Immune System—EGFR—chronic obstructive pulmonary disease	8.63e-06	3.82e-05	CbGpPWpGaD
Nilotinib—CYP2C8—Metabolism—CTGF—chronic obstructive pulmonary disease	8.62e-06	3.81e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Innate Immune System—IL6—chronic obstructive pulmonary disease	8.6e-06	3.81e-05	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—EDN1—chronic obstructive pulmonary disease	8.56e-06	3.79e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Immune System—IL1B—chronic obstructive pulmonary disease	8.56e-06	3.79e-05	CbGpPWpGaD
Nilotinib—MAPK8—Signaling Pathways—MMP9—chronic obstructive pulmonary disease	8.52e-06	3.77e-05	CbGpPWpGaD
Nilotinib—LYN—Signaling Pathways—LEP—chronic obstructive pulmonary disease	8.5e-06	3.76e-05	CbGpPWpGaD
Nilotinib—MAPK11—Immune System—EGFR—chronic obstructive pulmonary disease	8.48e-06	3.75e-05	CbGpPWpGaD
Nilotinib—MAPK11—Signaling Pathways—NOS3—chronic obstructive pulmonary disease	8.46e-06	3.74e-05	CbGpPWpGaD
Nilotinib—LYN—Innate Immune System—IL6—chronic obstructive pulmonary disease	8.42e-06	3.73e-05	CbGpPWpGaD
Nilotinib—ABL1—Innate Immune System—IL6—chronic obstructive pulmonary disease	8.39e-06	3.71e-05	CbGpPWpGaD
Nilotinib—LCK—Hemostasis—TP53—chronic obstructive pulmonary disease	8.38e-06	3.71e-05	CbGpPWpGaD
Nilotinib—LYN—Immune System—IL1B—chronic obstructive pulmonary disease	8.38e-06	3.71e-05	CbGpPWpGaD
Nilotinib—BRAF—Signaling Pathways—NOS3—chronic obstructive pulmonary disease	8.38e-06	3.71e-05	CbGpPWpGaD
Nilotinib—ABL1—Immune System—IL1B—chronic obstructive pulmonary disease	8.34e-06	3.69e-05	CbGpPWpGaD
Nilotinib—HCK—Disease—IL6—chronic obstructive pulmonary disease	8.33e-06	3.69e-05	CbGpPWpGaD
Nilotinib—ABCB1—Metabolism—GSTT1—chronic obstructive pulmonary disease	8.33e-06	3.68e-05	CbGpPWpGaD
Nilotinib—ABCB1—Metabolism—GCLC—chronic obstructive pulmonary disease	8.23e-06	3.64e-05	CbGpPWpGaD
Nilotinib—MAPK8—Immune System—IL6—chronic obstructive pulmonary disease	8.18e-06	3.62e-05	CbGpPWpGaD
Nilotinib—BLK—Immune System—IL6—chronic obstructive pulmonary disease	8.18e-06	3.62e-05	CbGpPWpGaD
Nilotinib—FGR—Immune System—IL6—chronic obstructive pulmonary disease	8.15e-06	3.61e-05	CbGpPWpGaD
Nilotinib—MAP2K5—Signaling Pathways—MMP9—chronic obstructive pulmonary disease	8.1e-06	3.58e-05	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—LEP—chronic obstructive pulmonary disease	8.06e-06	3.56e-05	CbGpPWpGaD
Nilotinib—KIT—Signaling Pathways—SERPINE1—chronic obstructive pulmonary disease	7.99e-06	3.53e-05	CbGpPWpGaD
Nilotinib—MAPK14—Innate Immune System—IL6—chronic obstructive pulmonary disease	7.99e-06	3.53e-05	CbGpPWpGaD
Nilotinib—MAPK14—Immune System—IL1B—chronic obstructive pulmonary disease	7.94e-06	3.51e-05	CbGpPWpGaD
Nilotinib—CYP2C8—Metabolism—CYP1A2—chronic obstructive pulmonary disease	7.94e-06	3.51e-05	CbGpPWpGaD
Nilotinib—BRAF—Disease—TGFB1—chronic obstructive pulmonary disease	7.91e-06	3.5e-05	CbGpPWpGaD
Nilotinib—CYP2D6—Metabolism—GSTT1—chronic obstructive pulmonary disease	7.85e-06	3.47e-05	CbGpPWpGaD
Nilotinib—CYP2B6—Metabolism—GSTP1—chronic obstructive pulmonary disease	7.82e-06	3.46e-05	CbGpPWpGaD
Nilotinib—LCK—Disease—SERPINE1—chronic obstructive pulmonary disease	7.81e-06	3.45e-05	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—ERBB3—chronic obstructive pulmonary disease	7.78e-06	3.44e-05	CbGpPWpGaD
Nilotinib—CYP2C9—Metabolism—GSTT1—chronic obstructive pulmonary disease	7.78e-06	3.44e-05	CbGpPWpGaD
Nilotinib—BRAF—Disease—EGFR—chronic obstructive pulmonary disease	7.76e-06	3.43e-05	CbGpPWpGaD
Nilotinib—CYP2D6—Metabolism—GCLC—chronic obstructive pulmonary disease	7.75e-06	3.43e-05	CbGpPWpGaD
Nilotinib—CYP2B6—Metabolism—HMOX1—chronic obstructive pulmonary disease	7.72e-06	3.41e-05	CbGpPWpGaD
Nilotinib—CYP2C9—Metabolism—GCLC—chronic obstructive pulmonary disease	7.69e-06	3.4e-05	CbGpPWpGaD
Nilotinib—KIT—Immune System—EGFR—chronic obstructive pulmonary disease	7.65e-06	3.38e-05	CbGpPWpGaD
Nilotinib—MAPK8—Signaling Pathways—VEGFA—chronic obstructive pulmonary disease	7.65e-06	3.38e-05	CbGpPWpGaD
Nilotinib—KIT—Signaling Pathways—NOS3—chronic obstructive pulmonary disease	7.63e-06	3.37e-05	CbGpPWpGaD
Nilotinib—PDGFRA—Signaling Pathways—SERPINE1—chronic obstructive pulmonary disease	7.56e-06	3.34e-05	CbGpPWpGaD
Nilotinib—ABCB1—Metabolism—CTGF—chronic obstructive pulmonary disease	7.51e-06	3.32e-05	CbGpPWpGaD
Nilotinib—MAPK11—Signaling Pathways—CXCL8—chronic obstructive pulmonary disease	7.5e-06	3.32e-05	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—HTR2A—chronic obstructive pulmonary disease	7.49e-06	3.31e-05	CbGpPWpGaD
Nilotinib—LCK—Disease—NOS3—chronic obstructive pulmonary disease	7.45e-06	3.3e-05	CbGpPWpGaD
Nilotinib—UGT1A1—Metabolism—ALB—chronic obstructive pulmonary disease	7.45e-06	3.3e-05	CbGpPWpGaD
Nilotinib—BRAF—Signaling Pathways—CXCL8—chronic obstructive pulmonary disease	7.43e-06	3.29e-05	CbGpPWpGaD
Nilotinib—ABCB1—Transmembrane transport of small molecules—ALB—chronic obstructive pulmonary disease	7.3e-06	3.23e-05	CbGpPWpGaD
Nilotinib—MAP2K5—Signaling Pathways—VEGFA—chronic obstructive pulmonary disease	7.27e-06	3.22e-05	CbGpPWpGaD
Nilotinib—PDGFRA—Immune System—EGFR—chronic obstructive pulmonary disease	7.24e-06	3.2e-05	CbGpPWpGaD
Nilotinib—PDGFRA—Signaling Pathways—NOS3—chronic obstructive pulmonary disease	7.22e-06	3.19e-05	CbGpPWpGaD
Nilotinib—KIT—Disease—TGFB1—chronic obstructive pulmonary disease	7.2e-06	3.19e-05	CbGpPWpGaD
Nilotinib—CYP2B6—Metabolism—GSTM1—chronic obstructive pulmonary disease	7.19e-06	3.18e-05	CbGpPWpGaD
Nilotinib—CYP2C9—Metabolism of lipids and lipoproteins—ALB—chronic obstructive pulmonary disease	7.17e-06	3.17e-05	CbGpPWpGaD
Nilotinib—UGT1A1—Metabolism—NOS3—chronic obstructive pulmonary disease	7.13e-06	3.15e-05	CbGpPWpGaD
Nilotinib—CYP2D6—Metabolism—CTGF—chronic obstructive pulmonary disease	7.08e-06	3.13e-05	CbGpPWpGaD
Nilotinib—KIT—Disease—EGFR—chronic obstructive pulmonary disease	7.06e-06	3.12e-05	CbGpPWpGaD
Nilotinib—MAPK8—Signaling Pathways—TGFB1—chronic obstructive pulmonary disease	7.02e-06	3.1e-05	CbGpPWpGaD
Nilotinib—CYP2C9—Metabolism—CTGF—chronic obstructive pulmonary disease	7.02e-06	3.1e-05	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—LEP—chronic obstructive pulmonary disease	6.97e-06	3.08e-05	CbGpPWpGaD
Nilotinib—ABCB1—Metabolism—CYP1A2—chronic obstructive pulmonary disease	6.92e-06	3.06e-05	CbGpPWpGaD
Nilotinib—LCK—Innate Immune System—IL6—chronic obstructive pulmonary disease	6.91e-06	3.05e-05	CbGpPWpGaD
Nilotinib—MAPK8—Signaling Pathways—EGFR—chronic obstructive pulmonary disease	6.88e-06	3.04e-05	CbGpPWpGaD
Nilotinib—LCK—Immune System—IL1B—chronic obstructive pulmonary disease	6.87e-06	3.04e-05	CbGpPWpGaD
Nilotinib—CYP2B6—Metabolism—CYP1A1—chronic obstructive pulmonary disease	6.82e-06	3.02e-05	CbGpPWpGaD
Nilotinib—PDGFRA—Disease—TGFB1—chronic obstructive pulmonary disease	6.82e-06	3.02e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling Pathways—SERPINE1—chronic obstructive pulmonary disease	6.81e-06	3.01e-05	CbGpPWpGaD
Nilotinib—MAPK11—Signaling Pathways—MMP9—chronic obstructive pulmonary disease	6.78e-06	3e-05	CbGpPWpGaD
Nilotinib—KIT—Signaling Pathways—CXCL8—chronic obstructive pulmonary disease	6.76e-06	2.99e-05	CbGpPWpGaD
Nilotinib—BRAF—Signaling Pathways—MMP9—chronic obstructive pulmonary disease	6.72e-06	2.97e-05	CbGpPWpGaD
Nilotinib—PDGFRA—Disease—EGFR—chronic obstructive pulmonary disease	6.68e-06	2.96e-05	CbGpPWpGaD
Nilotinib—MAP2K5—Signaling Pathways—TGFB1—chronic obstructive pulmonary disease	6.67e-06	2.95e-05	CbGpPWpGaD
Nilotinib—LYN—Signaling Pathways—SERPINE1—chronic obstructive pulmonary disease	6.67e-06	2.95e-05	CbGpPWpGaD
Nilotinib—CYP2C8—Metabolism—GSTP1—chronic obstructive pulmonary disease	6.62e-06	2.93e-05	CbGpPWpGaD
Nilotinib—MAP2K5—Signaling Pathways—EGFR—chronic obstructive pulmonary disease	6.54e-06	2.89e-05	CbGpPWpGaD
Nilotinib—CYP2C8—Metabolism—HMOX1—chronic obstructive pulmonary disease	6.53e-06	2.89e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Immune System—EGFR—chronic obstructive pulmonary disease	6.52e-06	2.88e-05	CbGpPWpGaD
Nilotinib—CYP2D6—Metabolism—CYP1A2—chronic obstructive pulmonary disease	6.52e-06	2.88e-05	CbGpPWpGaD
Nilotinib—MAPK11—Immune System—IL6—chronic obstructive pulmonary disease	6.52e-06	2.88e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling Pathways—NOS3—chronic obstructive pulmonary disease	6.5e-06	2.88e-05	CbGpPWpGaD
Nilotinib—CYP2C9—Metabolism—CYP1A2—chronic obstructive pulmonary disease	6.46e-06	2.86e-05	CbGpPWpGaD
Nilotinib—PDGFRA—Signaling Pathways—CXCL8—chronic obstructive pulmonary disease	6.4e-06	2.83e-05	CbGpPWpGaD
Nilotinib—LYN—Immune System—EGFR—chronic obstructive pulmonary disease	6.38e-06	2.82e-05	CbGpPWpGaD
Nilotinib—LYN—Signaling Pathways—NOS3—chronic obstructive pulmonary disease	6.37e-06	2.82e-05	CbGpPWpGaD
Nilotinib—ABL1—Immune System—EGFR—chronic obstructive pulmonary disease	6.35e-06	2.81e-05	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—SERPINE1—chronic obstructive pulmonary disease	6.32e-06	2.8e-05	CbGpPWpGaD
Nilotinib—ABCG2—Metabolism—ALB—chronic obstructive pulmonary disease	6.32e-06	2.8e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Disease—TGFB1—chronic obstructive pulmonary disease	6.14e-06	2.72e-05	CbGpPWpGaD
Nilotinib—KIT—Signaling Pathways—MMP9—chronic obstructive pulmonary disease	6.12e-06	2.71e-05	CbGpPWpGaD
Nilotinib—MAPK11—Signaling Pathways—VEGFA—chronic obstructive pulmonary disease	6.09e-06	2.7e-05	CbGpPWpGaD
Nilotinib—CYP2C8—Metabolism—GSTM1—chronic obstructive pulmonary disease	6.09e-06	2.69e-05	CbGpPWpGaD
Nilotinib—MAPK14—Immune System—EGFR—chronic obstructive pulmonary disease	6.05e-06	2.68e-05	CbGpPWpGaD
Nilotinib—ABCG2—Metabolism—NOS3—chronic obstructive pulmonary disease	6.05e-06	2.67e-05	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—NOS3—chronic obstructive pulmonary disease	6.04e-06	2.67e-05	CbGpPWpGaD
Nilotinib—BRAF—Signaling Pathways—VEGFA—chronic obstructive pulmonary disease	6.04e-06	2.67e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Disease—EGFR—chronic obstructive pulmonary disease	6.02e-06	2.66e-05	CbGpPWpGaD
Nilotinib—BRAF—Disease—IL6—chronic obstructive pulmonary disease	5.96e-06	2.64e-05	CbGpPWpGaD
Nilotinib—KIT—Immune System—IL6—chronic obstructive pulmonary disease	5.88e-06	2.6e-05	CbGpPWpGaD
Nilotinib—PDGFRA—Signaling Pathways—MMP9—chronic obstructive pulmonary disease	5.79e-06	2.56e-05	CbGpPWpGaD
Nilotinib—MAPK8—Signaling Pathways—TP53—chronic obstructive pulmonary disease	5.78e-06	2.56e-05	CbGpPWpGaD
Nilotinib—ABCB1—Metabolism—GSTP1—chronic obstructive pulmonary disease	5.77e-06	2.55e-05	CbGpPWpGaD
Nilotinib—CYP2C8—Metabolism—CYP1A1—chronic obstructive pulmonary disease	5.77e-06	2.55e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling Pathways—CXCL8—chronic obstructive pulmonary disease	5.77e-06	2.55e-05	CbGpPWpGaD
Nilotinib—ABCB1—Metabolism—HMOX1—chronic obstructive pulmonary disease	5.69e-06	2.52e-05	CbGpPWpGaD
Nilotinib—LYN—Signaling Pathways—CXCL8—chronic obstructive pulmonary disease	5.65e-06	2.5e-05	CbGpPWpGaD
Nilotinib—MAPK11—Signaling Pathways—TGFB1—chronic obstructive pulmonary disease	5.59e-06	2.47e-05	CbGpPWpGaD
Nilotinib—PDGFRA—Immune System—IL6—chronic obstructive pulmonary disease	5.56e-06	2.46e-05	CbGpPWpGaD
Nilotinib—BRAF—Signaling Pathways—TGFB1—chronic obstructive pulmonary disease	5.54e-06	2.45e-05	CbGpPWpGaD
Nilotinib—KIT—Signaling Pathways—VEGFA—chronic obstructive pulmonary disease	5.49e-06	2.43e-05	CbGpPWpGaD
Nilotinib—MAP2K5—Signaling Pathways—TP53—chronic obstructive pulmonary disease	5.49e-06	2.43e-05	CbGpPWpGaD
Nilotinib—MAPK11—Signaling Pathways—EGFR—chronic obstructive pulmonary disease	5.48e-06	2.43e-05	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—SERPINE1—chronic obstructive pulmonary disease	5.47e-06	2.42e-05	CbGpPWpGaD
Nilotinib—CYP2D6—Metabolism—GSTP1—chronic obstructive pulmonary disease	5.44e-06	2.41e-05	CbGpPWpGaD
Nilotinib—BRAF—Signaling Pathways—EGFR—chronic obstructive pulmonary disease	5.43e-06	2.4e-05	CbGpPWpGaD
Nilotinib—KIT—Disease—IL6—chronic obstructive pulmonary disease	5.43e-06	2.4e-05	CbGpPWpGaD
Nilotinib—CYP2C9—Metabolism—GSTP1—chronic obstructive pulmonary disease	5.39e-06	2.38e-05	CbGpPWpGaD
Nilotinib—CYP2D6—Metabolism—HMOX1—chronic obstructive pulmonary disease	5.36e-06	2.37e-05	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—CXCL8—chronic obstructive pulmonary disease	5.35e-06	2.37e-05	CbGpPWpGaD
Nilotinib—CYP2C9—Metabolism—HMOX1—chronic obstructive pulmonary disease	5.32e-06	2.35e-05	CbGpPWpGaD
Nilotinib—ABCB1—Metabolism—GSTM1—chronic obstructive pulmonary disease	5.3e-06	2.35e-05	CbGpPWpGaD
Nilotinib—MAPK8—Signaling Pathways—IL6—chronic obstructive pulmonary disease	5.29e-06	2.34e-05	CbGpPWpGaD
Nilotinib—LCK—Immune System—EGFR—chronic obstructive pulmonary disease	5.23e-06	2.32e-05	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—NOS3—chronic obstructive pulmonary disease	5.22e-06	2.31e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling Pathways—MMP9—chronic obstructive pulmonary disease	5.22e-06	2.31e-05	CbGpPWpGaD
Nilotinib—PDGFRA—Signaling Pathways—VEGFA—chronic obstructive pulmonary disease	5.2e-06	2.3e-05	CbGpPWpGaD
Nilotinib—PDGFRA—Disease—IL6—chronic obstructive pulmonary disease	5.14e-06	2.27e-05	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—GSTT1—chronic obstructive pulmonary disease	5.13e-06	2.27e-05	CbGpPWpGaD
Nilotinib—LYN—Signaling Pathways—MMP9—chronic obstructive pulmonary disease	5.11e-06	2.26e-05	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—GCLC—chronic obstructive pulmonary disease	5.07e-06	2.24e-05	CbGpPWpGaD
Nilotinib—KIT—Signaling Pathways—TGFB1—chronic obstructive pulmonary disease	5.04e-06	2.23e-05	CbGpPWpGaD
Nilotinib—MAP2K5—Signaling Pathways—IL6—chronic obstructive pulmonary disease	5.03e-06	2.22e-05	CbGpPWpGaD
Nilotinib—ABCB1—Metabolism—CYP1A1—chronic obstructive pulmonary disease	5.03e-06	2.22e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Immune System—IL6—chronic obstructive pulmonary disease	5.01e-06	2.22e-05	CbGpPWpGaD
Nilotinib—CYP2D6—Metabolism—GSTM1—chronic obstructive pulmonary disease	5e-06	2.21e-05	CbGpPWpGaD
Nilotinib—CYP2C9—Metabolism—GSTM1—chronic obstructive pulmonary disease	4.95e-06	2.19e-05	CbGpPWpGaD
Nilotinib—KIT—Signaling Pathways—EGFR—chronic obstructive pulmonary disease	4.94e-06	2.19e-05	CbGpPWpGaD
Nilotinib—LCK—Disease—TGFB1—chronic obstructive pulmonary disease	4.93e-06	2.18e-05	CbGpPWpGaD
Nilotinib—LYN—Immune System—IL6—chronic obstructive pulmonary disease	4.91e-06	2.17e-05	CbGpPWpGaD
Nilotinib—ABL1—Immune System—IL6—chronic obstructive pulmonary disease	4.88e-06	2.16e-05	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—MMP9—chronic obstructive pulmonary disease	4.84e-06	2.14e-05	CbGpPWpGaD
Nilotinib—LCK—Disease—EGFR—chronic obstructive pulmonary disease	4.83e-06	2.14e-05	CbGpPWpGaD
Nilotinib—PDGFRA—Signaling Pathways—TGFB1—chronic obstructive pulmonary disease	4.77e-06	2.11e-05	CbGpPWpGaD
Nilotinib—CYP2D6—Metabolism—CYP1A1—chronic obstructive pulmonary disease	4.74e-06	2.1e-05	CbGpPWpGaD
Nilotinib—CYP2C9—Metabolism—CYP1A1—chronic obstructive pulmonary disease	4.7e-06	2.08e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling Pathways—VEGFA—chronic obstructive pulmonary disease	4.68e-06	2.07e-05	CbGpPWpGaD
Nilotinib—PDGFRA—Signaling Pathways—EGFR—chronic obstructive pulmonary disease	4.68e-06	2.07e-05	CbGpPWpGaD
Nilotinib—MAPK14—Immune System—IL6—chronic obstructive pulmonary disease	4.65e-06	2.06e-05	CbGpPWpGaD
Nilotinib—CYP2B6—Metabolism—ALB—chronic obstructive pulmonary disease	4.63e-06	2.05e-05	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—CXCL8—chronic obstructive pulmonary disease	4.63e-06	2.05e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Disease—IL6—chronic obstructive pulmonary disease	4.63e-06	2.05e-05	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—CTGF—chronic obstructive pulmonary disease	4.63e-06	2.05e-05	CbGpPWpGaD
Nilotinib—MAPK11—Signaling Pathways—TP53—chronic obstructive pulmonary disease	4.6e-06	2.04e-05	CbGpPWpGaD
Nilotinib—LYN—Signaling Pathways—VEGFA—chronic obstructive pulmonary disease	4.59e-06	2.03e-05	CbGpPWpGaD
Nilotinib—BRAF—Signaling Pathways—TP53—chronic obstructive pulmonary disease	4.56e-06	2.02e-05	CbGpPWpGaD
Nilotinib—CYP2B6—Metabolism—NOS3—chronic obstructive pulmonary disease	4.43e-06	1.96e-05	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—VEGFA—chronic obstructive pulmonary disease	4.35e-06	1.92e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling Pathways—TGFB1—chronic obstructive pulmonary disease	4.3e-06	1.9e-05	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—CYP1A2—chronic obstructive pulmonary disease	4.26e-06	1.89e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling Pathways—EGFR—chronic obstructive pulmonary disease	4.22e-06	1.87e-05	CbGpPWpGaD
Nilotinib—MAPK11—Signaling Pathways—IL6—chronic obstructive pulmonary disease	4.21e-06	1.86e-05	CbGpPWpGaD
Nilotinib—LYN—Signaling Pathways—TGFB1—chronic obstructive pulmonary disease	4.21e-06	1.86e-05	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—MMP9—chronic obstructive pulmonary disease	4.19e-06	1.85e-05	CbGpPWpGaD
Nilotinib—BRAF—Signaling Pathways—IL6—chronic obstructive pulmonary disease	4.17e-06	1.85e-05	CbGpPWpGaD
Nilotinib—KIT—Signaling Pathways—TP53—chronic obstructive pulmonary disease	4.15e-06	1.84e-05	CbGpPWpGaD
Nilotinib—LYN—Signaling Pathways—EGFR—chronic obstructive pulmonary disease	4.13e-06	1.83e-05	CbGpPWpGaD
Nilotinib—LCK—Immune System—IL6—chronic obstructive pulmonary disease	4.02e-06	1.78e-05	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—TGFB1—chronic obstructive pulmonary disease	3.99e-06	1.77e-05	CbGpPWpGaD
Nilotinib—PDGFRA—Signaling Pathways—TP53—chronic obstructive pulmonary disease	3.93e-06	1.74e-05	CbGpPWpGaD
Nilotinib—CYP2C8—Metabolism—ALB—chronic obstructive pulmonary disease	3.92e-06	1.74e-05	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—EGFR—chronic obstructive pulmonary disease	3.91e-06	1.73e-05	CbGpPWpGaD
Nilotinib—KIT—Signaling Pathways—IL6—chronic obstructive pulmonary disease	3.8e-06	1.68e-05	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—VEGFA—chronic obstructive pulmonary disease	3.76e-06	1.66e-05	CbGpPWpGaD
Nilotinib—CYP2C8—Metabolism—NOS3—chronic obstructive pulmonary disease	3.75e-06	1.66e-05	CbGpPWpGaD
Nilotinib—LCK—Disease—IL6—chronic obstructive pulmonary disease	3.71e-06	1.64e-05	CbGpPWpGaD
Nilotinib—PDGFRA—Signaling Pathways—IL6—chronic obstructive pulmonary disease	3.6e-06	1.59e-05	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—GSTP1—chronic obstructive pulmonary disease	3.56e-06	1.57e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling Pathways—TP53—chronic obstructive pulmonary disease	3.54e-06	1.57e-05	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—HMOX1—chronic obstructive pulmonary disease	3.51e-06	1.55e-05	CbGpPWpGaD
Nilotinib—LYN—Signaling Pathways—TP53—chronic obstructive pulmonary disease	3.47e-06	1.53e-05	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—TGFB1—chronic obstructive pulmonary disease	3.45e-06	1.53e-05	CbGpPWpGaD
Nilotinib—ABCB1—Metabolism—ALB—chronic obstructive pulmonary disease	3.42e-06	1.51e-05	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—EGFR—chronic obstructive pulmonary disease	3.38e-06	1.5e-05	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—TP53—chronic obstructive pulmonary disease	3.29e-06	1.45e-05	CbGpPWpGaD
Nilotinib—ABCB1—Metabolism—NOS3—chronic obstructive pulmonary disease	3.27e-06	1.45e-05	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—GSTM1—chronic obstructive pulmonary disease	3.27e-06	1.45e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling Pathways—IL6—chronic obstructive pulmonary disease	3.24e-06	1.43e-05	CbGpPWpGaD
Nilotinib—CYP2D6—Metabolism—ALB—chronic obstructive pulmonary disease	3.22e-06	1.42e-05	CbGpPWpGaD
Nilotinib—CYP2C9—Metabolism—ALB—chronic obstructive pulmonary disease	3.19e-06	1.41e-05	CbGpPWpGaD
Nilotinib—LYN—Signaling Pathways—IL6—chronic obstructive pulmonary disease	3.17e-06	1.4e-05	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—CYP1A1—chronic obstructive pulmonary disease	3.1e-06	1.37e-05	CbGpPWpGaD
Nilotinib—CYP2D6—Metabolism—NOS3—chronic obstructive pulmonary disease	3.08e-06	1.36e-05	CbGpPWpGaD
Nilotinib—CYP2C9—Metabolism—NOS3—chronic obstructive pulmonary disease	3.05e-06	1.35e-05	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—IL6—chronic obstructive pulmonary disease	3.01e-06	1.33e-05	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—TP53—chronic obstructive pulmonary disease	2.84e-06	1.26e-05	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—IL6—chronic obstructive pulmonary disease	2.6e-06	1.15e-05	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—ALB—chronic obstructive pulmonary disease	2.11e-06	9.31e-06	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—NOS3—chronic obstructive pulmonary disease	2.01e-06	8.91e-06	CbGpPWpGaD
